Marc Durian

Age-Adjusted D-Dimer Cutoff Levels to Rule Out Pulmonary Embolism

Marc Righini, Josien van Es, Paul L. den Exter et al. · JAMA · 2014 · 941 citations · Full text

Medicine, Geriatric Medicine, Internal Medicine +13

Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

Michèle Cavo, Francesca Gay, Meral Beksaç et al. · The Lancet Haematology · 2020 · 384 citations · Full text

Medicine, Hematology, Oncology +17

Rituximab in patients with primary CNS lymphoma (HOVON 105/ALLG NHL 24): a randomised, open-label, phase 3 intergroup study

Jacoline E. C. Bromberg, Samar Issa, Katerina Bakunina et al. · The Lancet Oncology · 2019 · 235 citations

Medicine, Oncology, Pharmacotherapy +10

Melphalan, prednisone, and lenalidomide versus melphalan, prednisone, and thalidomide in untreated multiple myeloma

Sonja Zweegman, Bronno van der Holt, Ulf‐Henrik Mellqvist et al. · Blood · 2016 · 112 citations · Full text

Medicine, Hematology, Oncology +14

Thromboembolic resolution assessed by CT pulmonary angiography after treatment for acute pulmonary embolism

Lucia J. M. Kroft, Petra Erkens, Renée A. Douma et al. · Thrombosis and Haemostasis · 2015 · 103 citations · Full text

Medicine, Internal Medicine, Radiology +17